Follistatin-344 results: what to expect and when

Human gene-therapy findings do not establish a dose for follistatin-344 protein vials.

Also called: FS344, FST344, FS-344, Follistatin 344.

Myostatin pathway · Myostatin- and activin-binding protein precursor.

Gene-vector administration is separate from direct protein exposure. Registrations do not establish results. A protein-injection evidence level is not established here.

Key studies

  • Becker gene transfer, six adults: Four of six improved walking distance after gene transfer; no randomized control. (source)
  • Myositis gene transfer, six adults: Walking gains were reported, but exercise, steroids and unequal follow-up limit attribution. (source)
  • Registry and early myositis cohort: Registry includes three early low-dose myositis patients beyond the two six-person publications. (source)
  • Duchenne gene transfer, phase 1/2: No dose-limiting toxicity was reported; the registry does not show improved walking at two years. (source)
  • Plasmid gene delivery, unreviewed report: An uncontrolled manuscript reports small body-composition changes and increased LDL cholesterol. (source)
  • Klotho plus follistatin plasmids: Completed registration has no posted results or verified clinical benefit. (source)

Related to Follistatin-344

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.